JP4550417B2 - プロスタグランジンｅｐ２及び／又はｅｐ４受容体のリガンドとしてのポリアゾリジノン化合物 - Google Patents
プロスタグランジンｅｐ２及び／又はｅｐ４受容体のリガンドとしてのポリアゾリジノン化合物 Download PDFInfo
- Publication number
- JP4550417B2 JP4550417B2 JP2003537631A JP2003537631A JP4550417B2 JP 4550417 B2 JP4550417 B2 JP 4550417B2 JP 2003537631 A JP2003537631 A JP 2003537631A JP 2003537631 A JP2003537631 A JP 2003537631A JP 4550417 B2 JP4550417 B2 JP 4550417B2
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- benzoic acid
- group
- oxopyrazolidine
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 227
- 150000003180 prostaglandins Chemical class 0.000 title abstract description 16
- 101150109738 Ptger4 gene Proteins 0.000 title abstract description 14
- 239000003446 ligand Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- -1 3- (hydroxyoctyl) -5-oxopyrazolidine-1-yl Chemical group 0.000 claims description 69
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 48
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000005711 Benzoic acid Substances 0.000 claims description 30
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- 235000010233 benzoic acid Nutrition 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000002837 carbocyclic group Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- XZWDACYVXIULCX-UHFFFAOYSA-N 4-[2-[2-(4-hydroxynonyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCCC(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 XZWDACYVXIULCX-UHFFFAOYSA-N 0.000 claims description 8
- KEQOYEUKTHDSDS-ALCCZGGFSA-N 4-[2-[2-[(z)-4-hydroxynon-2-enyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCCC(O)\C=C/CN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 KEQOYEUKTHDSDS-ALCCZGGFSA-N 0.000 claims description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 8
- 230000035558 fertility Effects 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- FXEVKFYZRMILMZ-UHFFFAOYSA-N 4-[2-[2-(3-hydroxy-5-methylhexyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CC(C)CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 FXEVKFYZRMILMZ-UHFFFAOYSA-N 0.000 claims description 7
- LBGUNFMRRVJPSG-UHFFFAOYSA-N 4-[2-[2-(4-hydroxy-4-methylheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCC(C)(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 LBGUNFMRRVJPSG-UHFFFAOYSA-N 0.000 claims description 7
- NTVVAIFSHLCKGX-UHFFFAOYSA-N 4-[2-[2-(4-hydroxynon-2-ynyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCCC(O)C#CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 NTVVAIFSHLCKGX-UHFFFAOYSA-N 0.000 claims description 7
- MGCQBMZFRDABAR-UHFFFAOYSA-N 4-[2-[2-[4-(1-ethylcyclobutyl)-4-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C1CC(=O)N(CCC=2C=CC(=CC=2)C(O)=O)N1CCCC(O)C1(CC)CCC1 MGCQBMZFRDABAR-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- SIGCFCMKKRESGW-UHFFFAOYSA-N 4-[2-[2-(3-cyclobutyl-3-hydroxypropyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C1CCC1C(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 SIGCFCMKKRESGW-UHFFFAOYSA-N 0.000 claims description 6
- UFNLOWRQRUZWKF-UHFFFAOYSA-N 4-[2-[2-(4-ethyl-4-hydroxyoctyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCC(O)(CC)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 UFNLOWRQRUZWKF-UHFFFAOYSA-N 0.000 claims description 6
- KEQOYEUKTHDSDS-FNORWQNLSA-N 4-[2-[2-[(e)-4-hydroxynon-2-enyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCCC(O)\C=C\CN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 KEQOYEUKTHDSDS-FNORWQNLSA-N 0.000 claims description 6
- KALXDWPKUYNCLA-UHFFFAOYSA-N 4-[2-[2-[3-hydroxy-4-(3-methylphenyl)butyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CC1=CC=CC(CC(O)CCN2N(C(=O)CC2)CCC=2C=CC(=CC=2)C(O)=O)=C1 KALXDWPKUYNCLA-UHFFFAOYSA-N 0.000 claims description 6
- GNZZMSRREAKILT-UHFFFAOYSA-N 4-[2-[2-[4-[1-(cyclopropylmethyl)cyclobutyl]-4-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C1CCC1(CC1CC1)C(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 GNZZMSRREAKILT-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- LTKCOAAEGIFTID-UHFFFAOYSA-N 4-[2-[2-(4-hydroxyoctyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCC(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 LTKCOAAEGIFTID-UHFFFAOYSA-N 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- INOWIYUOGGMVDM-UHFFFAOYSA-N 4-[2-[2-(4-hydroxy-6-methylheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CC(C)CC(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 INOWIYUOGGMVDM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- JVPGVILOMSPMMY-UHFFFAOYSA-N 4-[2-[2-(3-hydroxy-4-phenylbutyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=CC=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 JVPGVILOMSPMMY-UHFFFAOYSA-N 0.000 claims description 3
- CALFSRIGIOMZFM-UHFFFAOYSA-N 4-[2-[2-(4-hydroxy-4,7-dimethyloctyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CC(C)CCC(C)(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 CALFSRIGIOMZFM-UHFFFAOYSA-N 0.000 claims description 3
- ZLJYTBPSXYKRKL-UHFFFAOYSA-N 4-[2-[2-(4-hydroxy-5-methyloctyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCC(C)C(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 ZLJYTBPSXYKRKL-UHFFFAOYSA-N 0.000 claims description 3
- KDVFFCPULSQTQN-UHFFFAOYSA-N 4-[2-[2-[3-hydroxy-4-(3-iodophenyl)butyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=CC(I)=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 KDVFFCPULSQTQN-UHFFFAOYSA-N 0.000 claims description 3
- NJNRRASCYIZRMY-UHFFFAOYSA-N 4-[2-[2-[4-(1,3-benzodioxol-5-yl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=C2OCOC2=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 NJNRRASCYIZRMY-UHFFFAOYSA-N 0.000 claims description 3
- MMKYRZFPISEJKE-UHFFFAOYSA-N 4-[2-[2-[4-(3-bromophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=CC(Br)=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 MMKYRZFPISEJKE-UHFFFAOYSA-N 0.000 claims description 3
- HVIXFTUMIDKUHX-UHFFFAOYSA-N 4-[2-[2-[4-(3-chlorophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=CC(Cl)=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 HVIXFTUMIDKUHX-UHFFFAOYSA-N 0.000 claims description 3
- XZXVFMOGPSLDSM-UHFFFAOYSA-N 4-[2-[2-[4-(3-fluorophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=CC(F)=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 XZXVFMOGPSLDSM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 239000002871 fertility agent Substances 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- ZOMMPOGASDFZJV-UWJYYQICSA-N 4-[2-[2-[(3s,4s)-3-hydroxy-4-phenylpentyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C([C@H](O)[C@@H](C)C=1C=CC=CC=1)CN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 ZOMMPOGASDFZJV-UWJYYQICSA-N 0.000 claims description 2
- ZOMMPOGASDFZJV-OQHSHRKDSA-N 4-[2-[2-[(4r)-3-hydroxy-4-phenylpentyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound OC([C@H](C)C=1C=CC=CC=1)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 ZOMMPOGASDFZJV-OQHSHRKDSA-N 0.000 claims description 2
- XXHJUODZNGBFDI-UHFFFAOYSA-N 4-[2-[2-[3-hydroxy-4-[3-(trifluoromethoxy)phenyl]butyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=CC(OC(F)(F)F)=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 XXHJUODZNGBFDI-UHFFFAOYSA-N 0.000 claims description 2
- UCAFZBFLCPWPLH-UHFFFAOYSA-N 4-[2-[2-[3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound C=1C=CC(C(F)(F)F)=CC=1CC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 UCAFZBFLCPWPLH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 1
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 1
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 1
- 208000011707 Ovulation disease Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 1
- 229940040129 luteinizing hormone Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 49
- 238000011282 treatment Methods 0.000 abstract description 40
- NDGRWYRVNANFNB-UHFFFAOYSA-N pyrazolidin-3-one Chemical class O=C1CCNN1 NDGRWYRVNANFNB-UHFFFAOYSA-N 0.000 abstract description 19
- 208000006673 asthma Diseases 0.000 abstract description 8
- 208000037765 diseases and disorders Diseases 0.000 abstract description 8
- 230000036512 infertility Effects 0.000 abstract description 8
- 231100000535 infertility Toxicity 0.000 abstract description 8
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 208000001132 Osteoporosis Diseases 0.000 abstract description 7
- 201000001880 Sexual dysfunction Diseases 0.000 abstract description 7
- 231100000872 sexual dysfunction Toxicity 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 208000020084 Bone disease Diseases 0.000 abstract description 6
- 230000001066 destructive effect Effects 0.000 abstract description 5
- 201000011461 pre-eclampsia Diseases 0.000 abstract description 5
- 208000006399 Premature Obstetric Labor Diseases 0.000 abstract description 4
- 208000021267 infertility disease Diseases 0.000 abstract description 3
- 208000002296 eclampsia Diseases 0.000 abstract description 2
- 208000012610 eosinophil disease Diseases 0.000 abstract description 2
- 230000023555 blood coagulation Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 278
- 239000000243 solution Substances 0.000 description 218
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 143
- 235000019439 ethyl acetate Nutrition 0.000 description 137
- 239000000203 mixture Substances 0.000 description 113
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 82
- 239000012230 colorless oil Substances 0.000 description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 62
- 239000012267 brine Substances 0.000 description 62
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 62
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 125000004432 carbon atom Chemical group C* 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 238000000746 purification Methods 0.000 description 51
- 238000003818 flash chromatography Methods 0.000 description 39
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 38
- 239000003921 oil Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 35
- 229910052938 sodium sulfate Inorganic materials 0.000 description 34
- 235000011152 sodium sulphate Nutrition 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 239000012047 saturated solution Substances 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 16
- 230000003197 catalytic effect Effects 0.000 description 15
- 241000124008 Mammalia Species 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000012298 atmosphere Substances 0.000 description 13
- 239000012299 nitrogen atmosphere Substances 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- 229930040373 Paraformaldehyde Natural products 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 229920002866 paraformaldehyde Polymers 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 230000002378 acidificating effect Effects 0.000 description 10
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 9
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001525 receptor binding assay Methods 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 229960002986 dinoprostone Drugs 0.000 description 7
- 208000000509 infertility Diseases 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 150000003462 sulfoxides Chemical class 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 208000037805 labour Diseases 0.000 description 5
- DBHOTPUMRDMPJQ-UHFFFAOYSA-N methyl 4-[2-[2-(4-hydroxy-4-methylnonyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCCCC(C)(O)CCCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 DBHOTPUMRDMPJQ-UHFFFAOYSA-N 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- QCIWZIYBBNEPKB-UHFFFAOYSA-N tert-butyl(dimethyl)silane Chemical compound C[SiH](C)C(C)(C)C QCIWZIYBBNEPKB-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241001274216 Naso Species 0.000 description 4
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 4
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000012911 assay medium Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000013262 cAMP assay Methods 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 description 4
- 239000008241 heterogeneous mixture Substances 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- PAVYSSGJRYCIIJ-UHFFFAOYSA-N 4-[2-[2-(3-hydroxyoctyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCCC(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 PAVYSSGJRYCIIJ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QDWZORFWJVTBDO-UHFFFAOYSA-N CCCCCC(C)(C=CCO)O[Si](C)(C)C(C)(C)C Chemical compound CCCCCC(C)(C=CCO)O[Si](C)(C)C(C)(C)C QDWZORFWJVTBDO-UHFFFAOYSA-N 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 206010036600 Premature labour Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 3
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 208000026440 premature labor Diseases 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 2
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 description 2
- KLTVSWGXIAYTHO-UHFFFAOYSA-N 1-Octen-3-one Chemical compound CCCCCC(=O)C=C KLTVSWGXIAYTHO-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- MPNDQUDYRDDDQH-UHFFFAOYSA-N 4-[2-[2-(3-hydroxy-4-methylheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCC(C)C(O)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 MPNDQUDYRDDDQH-UHFFFAOYSA-N 0.000 description 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000027004 Eosinophilic disease Diseases 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 238000003744 In vitro fertilisation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000002968 Tamarix aphylla Species 0.000 description 2
- 235000010197 Tamarix aphylla Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- DZTUYZMEUWMMEO-UHFFFAOYSA-N methyl 4-[2-[2-[3-hydroxy-4-(3-methylphenyl)butyl]-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCN1C(=O)CCN1CCC(O)CC1=CC=CC(C)=C1 DZTUYZMEUWMMEO-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- MFAVFTVSWZTMIC-UHFFFAOYSA-N (1-ethylcyclobutyl)methanol Chemical compound CCC1(CO)CCC1 MFAVFTVSWZTMIC-UHFFFAOYSA-N 0.000 description 1
- YJBGBBSAXCXJFC-VGMFFHCQSA-N (2S)-2-phenylpropanoic acid Chemical compound C1(=CC=CC=C1)[C@@H](C(=O)O)C.C1(=CC=CC=C1)[C@@H](C(=O)O)C YJBGBBSAXCXJFC-VGMFFHCQSA-N 0.000 description 1
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- YPGCWEMNNLXISK-SSDOTTSWSA-N (R)-hydratropic acid Chemical compound OC(=O)[C@H](C)C1=CC=CC=C1 YPGCWEMNNLXISK-SSDOTTSWSA-N 0.000 description 1
- VSMOENVRRABVKN-MRVPVSSYSA-N (S)-oct-1-en-3-ol Chemical compound CCCCC[C@H](O)C=C VSMOENVRRABVKN-MRVPVSSYSA-N 0.000 description 1
- KILFQBVAYASINW-ZRDIBKRKSA-N (e)-4-[tert-butyl(dimethyl)silyl]oxynon-2-en-1-ol Chemical compound CCCCCC(O[Si](C)(C)C(C)(C)C)\C=C\CO KILFQBVAYASINW-ZRDIBKRKSA-N 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N (trimethylsilyl)diazomethane Substances C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- KILFQBVAYASINW-BENRWUELSA-N (z)-4-[tert-butyl(dimethyl)silyl]oxynon-2-en-1-ol Chemical compound CCCCCC(O[Si](C)(C)C(C)(C)C)\C=C/CO KILFQBVAYASINW-BENRWUELSA-N 0.000 description 1
- 0 *N(CC1)N(*)C1=O Chemical compound *N(CC1)N(*)C1=O 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical group C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- SJYGAOCYTYPXRR-UHFFFAOYSA-N 1-(3-methylphenyl)but-3-en-2-one Chemical compound CC1=CC=CC(CC(=O)C=C)=C1 SJYGAOCYTYPXRR-UHFFFAOYSA-N 0.000 description 1
- NCQNLBQFBIPXJW-UHFFFAOYSA-N 1-(cyclopropylmethyl)cyclobutane-1-carbaldehyde Chemical compound C1CC1CC1(C=O)CCC1 NCQNLBQFBIPXJW-UHFFFAOYSA-N 0.000 description 1
- LPBPYHPNUCDBEV-UHFFFAOYSA-N 1-(cyclopropylmethyl)cyclobutane-1-carboxylic acid Chemical compound C1CC1CC1(C(=O)O)CCC1 LPBPYHPNUCDBEV-UHFFFAOYSA-N 0.000 description 1
- FUQXWFOBGMFYTP-UHFFFAOYSA-N 1-bromonon-2-yn-4-yloxy-tert-butyl-dimethylsilane Chemical compound CCCCCC(O[Si](C)(C)C(C)(C)C)C#CCBr FUQXWFOBGMFYTP-UHFFFAOYSA-N 0.000 description 1
- FTHUFBUZFDIYSA-UHFFFAOYSA-N 1-ethylcyclobutane-1-carbaldehyde Chemical compound CCC1(C=O)CCC1 FTHUFBUZFDIYSA-UHFFFAOYSA-N 0.000 description 1
- XLUXAKJPHJEFKL-UHFFFAOYSA-N 1-ethylcyclobutane-1-carboxylic acid Chemical compound CCC1(C(O)=O)CCC1 XLUXAKJPHJEFKL-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- ODVLMCWNGKLROU-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCOC2=C1 ODVLMCWNGKLROU-UHFFFAOYSA-N 0.000 description 1
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 1
- WFPMUFXQDKMVCO-UHFFFAOYSA-N 2-(3-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1 WFPMUFXQDKMVCO-UHFFFAOYSA-N 0.000 description 1
- YEAUYVGUXSZCFI-UHFFFAOYSA-N 2-(3-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(F)=C1 YEAUYVGUXSZCFI-UHFFFAOYSA-N 0.000 description 1
- MRSWWBAFGGGWRH-UHFFFAOYSA-N 2-(3-iodophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(I)=C1 MRSWWBAFGGGWRH-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- HYYFSLNJFJFUJC-UHFFFAOYSA-N 2-[2-[4-[tert-butyl(dimethyl)silyl]oxynon-2-ynyl]-5-oxopyrazolidin-1-yl]ethyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCCN1N(CCC1=O)CC#CC(CCCCC)O[Si](C)(C)C(C)(C)C HYYFSLNJFJFUJC-UHFFFAOYSA-N 0.000 description 1
- RIYFONBSYWACFF-UHFFFAOYSA-N 2-bromoethylcyclopropane Chemical compound BrCCC1CC1 RIYFONBSYWACFF-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- PXAJJJAARKLWRO-UHFFFAOYSA-N 2-methyl-4-[2-[2-(4-methyl-3-oxoheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCC(C)C(=O)CCN1CCC(=O)N1CCC2=CC(=C(C=C2)C(=O)O)C PXAJJJAARKLWRO-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- RVLMPMSTVASLIS-UHFFFAOYSA-N 3-ethylhept-1-en-3-ol Chemical compound C(C)C(C=C)(CCCC)O RVLMPMSTVASLIS-UHFFFAOYSA-N 0.000 description 1
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 description 1
- JNLMZYGDTPRAMM-UHFFFAOYSA-N 3-methylhex-1-en-3-ol Chemical compound CCCC(C)(O)C=C JNLMZYGDTPRAMM-UHFFFAOYSA-N 0.000 description 1
- DRKRLMZMGTWUSQ-UHFFFAOYSA-N 3-methyloct-1-en-3-ol Chemical compound CCCCCC(C)(O)C=C DRKRLMZMGTWUSQ-UHFFFAOYSA-N 0.000 description 1
- BKMRWJWLBHHGCF-UHFFFAOYSA-N 4-(2-bromoethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CCBr)C=C1 BKMRWJWLBHHGCF-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical class CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- GJZASXQIHCEQGK-UHFFFAOYSA-N 4-[2-[2-(3-hydroxy-5-methylheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCC(C)CC(CCN1CCC(=O)N1CCC2=CC=C(C=C2)C(=O)O)O GJZASXQIHCEQGK-UHFFFAOYSA-N 0.000 description 1
- JXYNCYFPLPRCTF-UHFFFAOYSA-N 4-[2-[2-(4-hydroxy-4-methylnonyl)-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound CCCCCC(C)(O)CCCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 JXYNCYFPLPRCTF-UHFFFAOYSA-N 0.000 description 1
- ZOMMPOGASDFZJV-PBVYKCSPSA-N 4-[2-[2-[(4s)-3-hydroxy-4-phenylpentyl]-5-oxopyrazolidin-1-yl]ethyl]benzoic acid Chemical compound OC([C@@H](C)C=1C=CC=CC=1)CCN1CCC(=O)N1CCC1=CC=C(C(O)=O)C=C1 ZOMMPOGASDFZJV-PBVYKCSPSA-N 0.000 description 1
- KILFQBVAYASINW-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxynon-2-en-1-ol Chemical compound CCCCCC(O[Si](C)(C)C(C)(C)C)C=CCO KILFQBVAYASINW-UHFFFAOYSA-N 0.000 description 1
- RGNIZKWAMRSFKU-UHFFFAOYSA-N 4-methylhept-1-en-3-ol Chemical compound CCCC(C)C(O)C=C RGNIZKWAMRSFKU-UHFFFAOYSA-N 0.000 description 1
- FMZDFRXBZBPNSU-UHFFFAOYSA-N 4-methylhept-1-en-3-one Chemical compound CCCC(C)C(=O)C=C FMZDFRXBZBPNSU-UHFFFAOYSA-N 0.000 description 1
- AZAKXXGZWJWZLN-UHFFFAOYSA-N 5-methylhex-1-en-3-ol Chemical compound CC(C)CC(O)C=C AZAKXXGZWJWZLN-UHFFFAOYSA-N 0.000 description 1
- CMXNFXBFNYHFAL-UHFFFAOYSA-N 5-methylhex-1-en-3-one Chemical compound CC(C)CC(=O)C=C CMXNFXBFNYHFAL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- IMUUFSXWBGMTHP-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC(C=CCO)C1(CCC1)CC2CC2 Chemical compound CC(C)(C)[Si](C)(C)OC(C=CCO)C1(CCC1)CC2CC2 IMUUFSXWBGMTHP-UHFFFAOYSA-N 0.000 description 1
- ZLJPWFMNWGPJIH-UHFFFAOYSA-N CC(C)(C)[Si](C)(C)OC(C=CCO)C1CCC1 Chemical compound CC(C)(C)[Si](C)(C)OC(C=CCO)C1CCC1 ZLJPWFMNWGPJIH-UHFFFAOYSA-N 0.000 description 1
- WLHPDCWDPAVCPZ-UHFFFAOYSA-N CC(C)CC(C)(C=C)O[Si](C)(C)C(C)(C)C Chemical compound CC(C)CC(C)(C=C)O[Si](C)(C)C(C)(C)C WLHPDCWDPAVCPZ-UHFFFAOYSA-N 0.000 description 1
- GJPCVQUURYZTQF-UHFFFAOYSA-N CC(C)CC(C)C=CC(O)O[Si](C)(C)C(C)(C)C Chemical compound CC(C)CC(C)C=CC(O)O[Si](C)(C)C(C)(C)C GJPCVQUURYZTQF-UHFFFAOYSA-N 0.000 description 1
- UDISEGOZWWPCQT-UHFFFAOYSA-N CCC1(CCC1)C(C=C)O Chemical compound CCC1(CCC1)C(C=C)O UDISEGOZWWPCQT-UHFFFAOYSA-N 0.000 description 1
- RYAHWVNHLVDKDF-FQEVSTJZSA-N CCC1(CCC1)[C@H](CCCN(CC1)N(CCc2ccc(C(O)=O)c(C)c2)C1=O)O Chemical compound CCC1(CCC1)[C@H](CCCN(CC1)N(CCc2ccc(C(O)=O)c(C)c2)C1=O)O RYAHWVNHLVDKDF-FQEVSTJZSA-N 0.000 description 1
- AEONIWXSUDVCHF-UHFFFAOYSA-N CCCC(C)(C=C)O[Si](C)(C)C(C)(C)C Chemical compound CCCC(C)(C=C)O[Si](C)(C)C(C)(C)C AEONIWXSUDVCHF-UHFFFAOYSA-N 0.000 description 1
- ZGSZTZNLBYMUDM-UHFFFAOYSA-N CCCC(C)(C=CCBr)O[Si](C)(C)C(C)(C)C Chemical compound CCCC(C)(C=CCBr)O[Si](C)(C)C(C)(C)C ZGSZTZNLBYMUDM-UHFFFAOYSA-N 0.000 description 1
- GXTCYQPQQFWOHS-UHFFFAOYSA-N CCCC(C)(C=CCO)O[Si](C)(C)C(C)(C)C Chemical compound CCCC(C)(C=CCO)O[Si](C)(C)C(C)(C)C GXTCYQPQQFWOHS-UHFFFAOYSA-N 0.000 description 1
- QXHMVGYUHYVNAS-UHFFFAOYSA-N CCCC(C)C(C=CCBr)O[Si](C)(C)C(C)(C)C Chemical compound CCCC(C)C(C=CCBr)O[Si](C)(C)C(C)(C)C QXHMVGYUHYVNAS-UHFFFAOYSA-N 0.000 description 1
- IOTPYJXPQHJPDB-UHFFFAOYSA-N CCCC(C)C(C=CCO)O[Si](C)(C)C(C)(C)C Chemical compound CCCC(C)C(C=CCO)O[Si](C)(C)C(C)(C)C IOTPYJXPQHJPDB-UHFFFAOYSA-N 0.000 description 1
- VGYOPWMBEDEYBL-UHFFFAOYSA-N CCCCC(C=CCBr)O[Si](C)(C)C(C)(C)C Chemical compound CCCCC(C=CCBr)O[Si](C)(C)C(C)(C)C VGYOPWMBEDEYBL-UHFFFAOYSA-N 0.000 description 1
- WUSQMSBBYAXXCG-UHFFFAOYSA-N CCCCC(C=CCN1CCC(=O)N1CCOC(=O)C2=CC=CC=C2)O[Si](C)(C)C(C)(C)C Chemical compound CCCCC(C=CCN1CCC(=O)N1CCOC(=O)C2=CC=CC=C2)O[Si](C)(C)C(C)(C)C WUSQMSBBYAXXCG-UHFFFAOYSA-N 0.000 description 1
- SYFADPHMUAHSLC-UHFFFAOYSA-N CCCCC(CC)(C=C)O[Si](C)(C)C(C)(C)C Chemical compound CCCCC(CC)(C=C)O[Si](C)(C)C(C)(C)C SYFADPHMUAHSLC-UHFFFAOYSA-N 0.000 description 1
- GWIDJGJBASIXBP-UHFFFAOYSA-N CCCCC(CC)(C=CCBr)O[Si](C)(C)C(C)(C)C Chemical compound CCCCC(CC)(C=CCBr)O[Si](C)(C)C(C)(C)C GWIDJGJBASIXBP-UHFFFAOYSA-N 0.000 description 1
- DRSNJMCYWBZUKN-UHFFFAOYSA-N CCCCC(CC)C=CC(C(C)(C)C)(O)O[Si](C)(C)CCCC Chemical compound CCCCC(CC)C=CC(C(C)(C)C)(O)O[Si](C)(C)CCCC DRSNJMCYWBZUKN-UHFFFAOYSA-N 0.000 description 1
- GUJDDLGIMZXJRX-UHFFFAOYSA-N CCCCC(CCCN(CC1)N(CCc(cc2)ccc2C(O)=O)C1=O)=O Chemical compound CCCCC(CCCN(CC1)N(CCc(cc2)ccc2C(O)=O)C1=O)=O GUJDDLGIMZXJRX-UHFFFAOYSA-N 0.000 description 1
- QQRBYYWTMJNDAF-UHFFFAOYSA-N CCCCC(O[Si](C)(C)C(C)(C)C)C=CCO Chemical compound CCCCC(O[Si](C)(C)C(C)(C)C)C=CCO QQRBYYWTMJNDAF-UHFFFAOYSA-N 0.000 description 1
- OPCBBEKRGWDRQZ-UHFFFAOYSA-N CCCCCC(O[Si](C)(C)C(C)(C)C)C=CCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 Chemical compound CCCCCC(O[Si](C)(C)C(C)(C)C)C=CCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 OPCBBEKRGWDRQZ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000021663 Female sexual arousal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 108010057021 Menotropins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- DCTQJZWBQROARN-UHFFFAOYSA-N OC(CCCN(CC1)N(CCC(C=CC=C2)=C2C(O)=O)C1=O)C1(CC2CC2)CCC1 Chemical compound OC(CCCN(CC1)N(CCC(C=CC=C2)=C2C(O)=O)C1=O)C1(CC2CC2)CCC1 DCTQJZWBQROARN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 1
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108010047196 Urofollitropin Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- WIDJSWAOMJJQDJ-BENRWUELSA-N [(Z)-1-bromonon-2-en-4-yl]oxy-tert-butyl-dimethylsilane Chemical compound BrC\C=C/C(CCCCC)O[Si](C)(C)C(C)(C)C WIDJSWAOMJJQDJ-BENRWUELSA-N 0.000 description 1
- WIDJSWAOMJJQDJ-ZRDIBKRKSA-N [(e)-1-bromonon-2-en-4-yl]oxy-tert-butyl-dimethylsilane Chemical compound CCCCCC(O[Si](C)(C)C(C)(C)C)\C=C\CBr WIDJSWAOMJJQDJ-ZRDIBKRKSA-N 0.000 description 1
- MKEZIQZDWDINDV-UHFFFAOYSA-N [1-(cyclopropylmethyl)cyclobutyl]methanol Chemical compound C1CC1CC1(CO)CCC1 MKEZIQZDWDINDV-UHFFFAOYSA-N 0.000 description 1
- FCVHBUFELUXTLR-UHFFFAOYSA-N [Li].[AlH3] Chemical compound [Li].[AlH3] FCVHBUFELUXTLR-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N alpha-phenylpropionic acid Natural products OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004152 benzoquinonyl group Chemical group C1(C(=CC(C=C1)=O)*)=O 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000032686 female pregnancy Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- PZKFYTOLVRCMOA-UHFFFAOYSA-N hept-1-en-3-ol Chemical compound CCCCC(O)C=C PZKFYTOLVRCMOA-UHFFFAOYSA-N 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- HNNUQHJWFIPTLJ-UHFFFAOYSA-N methyl 4-(2-bromoethyl)benzoate Chemical compound COC(=O)C1=CC=C(CCBr)C=C1 HNNUQHJWFIPTLJ-UHFFFAOYSA-N 0.000 description 1
- NKBOAXUGPIMYAA-UHFFFAOYSA-N methyl 4-[2-[2-(3-cyclobutyl-3-hydroxypropyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCN1C(=O)CCN1CCC(O)C1CCC1 NKBOAXUGPIMYAA-UHFFFAOYSA-N 0.000 description 1
- AUQUEKQUKQVRTD-UHFFFAOYSA-N methyl 4-[2-[2-(3-cyclobutyl-3-oxopropyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCN1C(=O)CCN1CCC(=O)C1CCC1 AUQUEKQUKQVRTD-UHFFFAOYSA-N 0.000 description 1
- NCLDGMWHWMMIGK-UHFFFAOYSA-N methyl 4-[2-[2-(3-hydroxy-5-methylhexyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCN1C(=O)CCN1CCC(O)CC(C)C NCLDGMWHWMMIGK-UHFFFAOYSA-N 0.000 description 1
- AJVLCBDBOKCCIQ-UHFFFAOYSA-N methyl 4-[2-[2-(4-ethyl-4-hydroxyoctyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCCC(O)(CC)CCCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 AJVLCBDBOKCCIQ-UHFFFAOYSA-N 0.000 description 1
- MPUNBPOVYKDPFG-UHFFFAOYSA-N methyl 4-[2-[2-(4-hydroxy-4-methylheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCC(C)(O)CCCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 MPUNBPOVYKDPFG-UHFFFAOYSA-N 0.000 description 1
- FJFYKTHRDGTVIM-UHFFFAOYSA-N methyl 4-[2-[2-(4-hydroxynon-2-ynyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCCCC(O)C#CCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 FJFYKTHRDGTVIM-UHFFFAOYSA-N 0.000 description 1
- XIBOXYWXDKNPGQ-UHFFFAOYSA-N methyl 4-[2-[2-(4-methyl-3-oxoheptyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCC(C)C(=O)CCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 XIBOXYWXDKNPGQ-UHFFFAOYSA-N 0.000 description 1
- GUMHMFKRILHNLH-UHFFFAOYSA-N methyl 4-[2-[2-(5-methyl-3-oxohexyl)-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCN1C(=O)CCN1CCC(=O)CC(C)C GUMHMFKRILHNLH-UHFFFAOYSA-N 0.000 description 1
- ZESHBQCNBHIALE-UHFFFAOYSA-N methyl 4-[2-[2-[4-(1-ethylcyclobutyl)-4-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound C1CC(=O)N(CCC=2C=CC(=CC=2)C(=O)OC)N1CCCC(O)C1(CC)CCC1 ZESHBQCNBHIALE-UHFFFAOYSA-N 0.000 description 1
- UFKBFEYSEDWQJE-UHFFFAOYSA-N methyl 4-[2-[2-[4-[1-(cyclopropylmethyl)cyclobutyl]-4-hydroxybutyl]-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CCN1C(=O)CCN1CCCC(O)C1(CC2CC2)CCC1 UFKBFEYSEDWQJE-UHFFFAOYSA-N 0.000 description 1
- BZTAWSYVBORUKN-UHFFFAOYSA-N methyl 4-[2-[2-[4-[tert-butyl(dimethyl)silyl]oxy-4-ethyloct-2-enyl]-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCCC(CC)(C=CCN1CCC(=O)N1CCC2=CC=C(C=C2)C(=O)OC)O[Si](C)(C)C(C)(C)C BZTAWSYVBORUKN-UHFFFAOYSA-N 0.000 description 1
- JJPAAKHAAXYCBG-UHFFFAOYSA-N methyl 4-[2-[2-[4-[tert-butyl(dimethyl)silyl]oxy-4-ethyloctyl]-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCCC(CC)(O[Si](C)(C)C(C)(C)C)CCCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 JJPAAKHAAXYCBG-UHFFFAOYSA-N 0.000 description 1
- XMUOYBIWERBMFS-UHFFFAOYSA-N methyl 4-[2-[2-[4-[tert-butyl(dimethyl)silyl]oxy-4-methylheptyl]-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CC(C)(C)[Si](C)(C)OC(C)(CCC)CCCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 XMUOYBIWERBMFS-UHFFFAOYSA-N 0.000 description 1
- CFJQZSUSLRAMOJ-UHFFFAOYSA-N methyl 4-[2-[2-[4-[tert-butyl(dimethyl)silyl]oxynonyl]-5-oxopyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCCCC(O[Si](C)(C)C(C)(C)C)CCCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 CFJQZSUSLRAMOJ-UHFFFAOYSA-N 0.000 description 1
- NEVCPSXEQHAUJE-UHFFFAOYSA-N methyl 4-[2-[5-oxo-2-(3-oxooctyl)pyrazolidin-1-yl]ethyl]benzoate Chemical compound CCCCCC(=O)CCN1CCC(=O)N1CCC1=CC=C(C(=O)OC)C=C1 NEVCPSXEQHAUJE-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- CKYUMEGJFNPHQR-UHFFFAOYSA-N n,n-diethylcyclobutanecarboxamide Chemical compound CCN(CC)C(=O)C1CCC1 CKYUMEGJFNPHQR-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- UPSCSLXQWAMPEG-UHFFFAOYSA-N n-methoxy-n-methyl-2-(3-methylphenyl)acetamide Chemical compound CON(C)C(=O)CC1=CC=CC(C)=C1 UPSCSLXQWAMPEG-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000012404 paroxysmal familial ventricular fibrillation Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000017953 prostanoid receptors Human genes 0.000 description 1
- 108050007059 prostanoid receptors Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- VUUDTUCWJNLDJM-UHFFFAOYSA-N tert-butyl 2-[2-(4-methoxycarbonylphenyl)ethyl]-3-oxopyrazolidine-1-carboxylate Chemical compound C1=CC(C(=O)OC)=CC=C1CCN1C(=O)CCN1C(=O)OC(C)(C)C VUUDTUCWJNLDJM-UHFFFAOYSA-N 0.000 description 1
- NBSOESDIACOLSN-UHFFFAOYSA-N tert-butyl-[1-[1-(cyclopropylmethyl)cyclobutyl]prop-2-enoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC(C=C)C1(CCC1)CC2CC2 NBSOESDIACOLSN-UHFFFAOYSA-N 0.000 description 1
- MMKOSVMWXHDGEI-UHFFFAOYSA-N tert-butyl-dimethyl-oct-1-yn-3-yloxysilane Chemical compound CCCCCC(C#C)O[Si](C)(C)C(C)(C)C MMKOSVMWXHDGEI-UHFFFAOYSA-N 0.000 description 1
- JKEKTIIXRLTEMN-UHFFFAOYSA-N tert-butyl-hept-1-en-3-yloxy-dimethylsilane Chemical compound [Si](C)(C)(C(C)(C)C)OC(C=C)CCCC JKEKTIIXRLTEMN-UHFFFAOYSA-N 0.000 description 1
- UNWUYTNKSRTDDC-UHFFFAOYSA-N tert-butylsilane Chemical compound CC(C)(C)[SiH3] UNWUYTNKSRTDDC-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33604801P | 2001-10-23 | 2001-10-23 | |
| PCT/US2002/033964 WO2003035064A1 (en) | 2001-10-23 | 2002-10-23 | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005509632A JP2005509632A (ja) | 2005-04-14 |
| JP2005509632A5 JP2005509632A5 (https=) | 2006-01-05 |
| JP4550417B2 true JP4550417B2 (ja) | 2010-09-22 |
Family
ID=23314338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003537631A Expired - Fee Related JP4550417B2 (ja) | 2001-10-23 | 2002-10-23 | プロスタグランジンｅｐ２及び／又はｅｐ４受容体のリガンドとしてのポリアゾリジノン化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7410991B2 (https=) |
| EP (1) | EP1439837B1 (https=) |
| JP (1) | JP4550417B2 (https=) |
| AT (1) | ATE391503T1 (https=) |
| AU (1) | AU2002340282B2 (https=) |
| CA (1) | CA2463102C (https=) |
| DE (1) | DE60226051T2 (https=) |
| ES (1) | ES2305310T3 (https=) |
| IL (2) | IL161581A0 (https=) |
| WO (1) | WO2003035064A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| CN101133037B (zh) * | 2005-01-27 | 2012-05-09 | 旭化成制药株式会社 | 六元杂环化合物及其用途 |
| US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US7557095B2 (en) * | 2006-05-12 | 2009-07-07 | Allergan, Inc. | Therapeutic compounds |
| WO2008021804A2 (en) * | 2006-08-09 | 2008-02-21 | Allergan, Inc. | Therapeutic amides and related compounds |
| US7507833B2 (en) * | 2006-08-10 | 2009-03-24 | Allergan, Inc. | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives |
| EP2147672A4 (en) | 2007-05-08 | 2011-11-02 | Nat University Corp Hamamatsu University School Of Medicine | CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST |
| EP2002838A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma AG | Verwendung von Aryl/Hetarylamid-Derivaten als Modulatoren des EP2-Rezeptors |
| EP2003118A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| EP2014287A1 (de) * | 2007-06-13 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Zimtsäurederivaten als Modulatoren des EP2-Rezeptors |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| JP2011519937A (ja) * | 2008-05-09 | 2011-07-14 | アラーガン インコーポレイテッド | 治療用ｎ‐アリールまたはｎ‐ヘテロアリールピラゾリジンおよびピラゾリジノン誘導体 |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| WO2011124525A1 (de) * | 2010-04-08 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
| EP2555773A1 (de) * | 2010-04-08 | 2013-02-13 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| WO2014015247A1 (en) | 2012-07-19 | 2014-01-23 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| PT2989098T (pt) | 2013-03-15 | 2017-08-16 | Cayman Chemical Co Inc | Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4 |
| US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| KR20160048054A (ko) | 2013-07-19 | 2016-05-03 | 카이맨 케미칼 컴파니 인코포레이티드 | 골 성장의 촉진을 위한 방법, 시스템 및 조성물 |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
| PT3733665T (pt) | 2017-12-25 | 2022-10-21 | Asahi Kasei Pharma Corp | Compostos contendo unidade de 2-oxo-1,3,4-tiadiazinan-3-ilo com atividade agonista do recetor ep4 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CA3125900A1 (en) | 2019-01-08 | 2020-07-16 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitor |
| US12304897B2 (en) | 2019-01-31 | 2025-05-20 | Kyorin Pharmaceutical Co., Ltd. | 15-PGDH inhibitors |
| GB202211234D0 (en) * | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2323193A1 (de) * | 1972-05-10 | 1973-11-22 | Du Pont | Pyrazolidinone |
| US3873566A (en) * | 1973-02-28 | 1975-03-25 | Du Pont | 3-Pyrazolidinones and pyrazolidines |
| DE2451160A1 (de) * | 1973-10-30 | 1975-05-07 | Du Pont | 3-pyrazolidinone und pyrazolidine |
| US4211876A (en) * | 1979-06-13 | 1980-07-08 | E. I. Du Pont De Nemours And Company | 3-Pyrazolidinone carboxamides |
| US5605814A (en) * | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
| GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
| TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
| TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
| EP0752421B1 (en) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
| KR20010074981A (ko) * | 1998-09-14 | 2001-08-09 | 우에노 도시오 | ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제 |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| IL141120A0 (en) * | 2000-01-31 | 2002-02-10 | Pfizer Prod Inc | Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
-
2002
- 2002-10-23 US US10/492,910 patent/US7410991B2/en not_active Expired - Fee Related
- 2002-10-23 ES ES02778630T patent/ES2305310T3/es not_active Expired - Lifetime
- 2002-10-23 CA CA2463102A patent/CA2463102C/en not_active Expired - Fee Related
- 2002-10-23 WO PCT/US2002/033964 patent/WO2003035064A1/en not_active Ceased
- 2002-10-23 AU AU2002340282A patent/AU2002340282B2/en not_active Ceased
- 2002-10-23 DE DE60226051T patent/DE60226051T2/de not_active Expired - Lifetime
- 2002-10-23 EP EP02778630A patent/EP1439837B1/en not_active Expired - Lifetime
- 2002-10-23 IL IL16158102A patent/IL161581A0/xx unknown
- 2002-10-23 AT AT02778630T patent/ATE391503T1/de not_active IP Right Cessation
- 2002-10-23 JP JP2003537631A patent/JP4550417B2/ja not_active Expired - Fee Related
-
2004
- 2004-04-22 IL IL161581A patent/IL161581A/en not_active IP Right Cessation
-
2008
- 2008-05-14 US US12/120,408 patent/US7863312B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003035064A1 (en) | 2003-05-01 |
| ATE391503T1 (de) | 2008-04-15 |
| US20080234346A1 (en) | 2008-09-25 |
| JP2005509632A (ja) | 2005-04-14 |
| DE60226051T2 (de) | 2009-05-20 |
| EP1439837B1 (en) | 2008-04-09 |
| AU2002340282B2 (en) | 2007-08-09 |
| EP1439837A1 (en) | 2004-07-28 |
| CA2463102A1 (en) | 2003-05-01 |
| DE60226051D1 (de) | 2008-05-21 |
| IL161581A (en) | 2010-11-30 |
| US20040254233A1 (en) | 2004-12-16 |
| US7863312B2 (en) | 2011-01-04 |
| US7410991B2 (en) | 2008-08-12 |
| CA2463102C (en) | 2011-05-10 |
| ES2305310T3 (es) | 2008-11-01 |
| IL161581A0 (en) | 2004-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4550417B2 (ja) | プロスタグランジンｅｐ２及び／又はｅｐ４受容体のリガンドとしてのポリアゾリジノン化合物 | |
| AU2002340282A1 (en) | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors | |
| US8058305B2 (en) | Pyrrolidine derivatives as prostaglandin modulators | |
| DE60307607T2 (de) | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten | |
| JP4754820B2 (ja) | プロスタグランジン作動薬としてのγラクタムおよびその使用 | |
| ZA200201485B (en) | N-Heterocyclic derivatives as NOS inhibitors. | |
| AU662073B2 (en) | Substituted cyclohexane derivatives, processes for their preparation and the use of the compounds for treating diseases | |
| SK18182002A3 (sk) | Deriváty glutaramidu substituované cyklopentylskupinou ako inhibítory neutrálnej endopeptidázy | |
| US6518282B1 (en) | 4-Arylpiperidine derivatives for the treatment of pruritus | |
| JP2002504547A (ja) | 新規複素環ジアリールメチレン誘導体、その調製方法及び治療におけるその使用 | |
| JPS62242669A (ja) | ド−パミン−β−ヒドロキシラ−ゼ抑制剤のエステルプロドラツグ | |
| JP5128954B2 (ja) | Ｄｐ１受容体アゴニストとして使用されるピロリジン−２−オン誘導体 | |
| JP2926168B2 (ja) | 含硫黄化合物 | |
| AU2011254072A1 (en) | Pyrrolidine derivatives as prostaglandin modulators | |
| JPH04108730A (ja) | アレルギー性疾患治療剤 | |
| JPH10512553A (ja) | 新規な化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050927 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050927 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080625 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090522 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100517 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100608 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100708 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130716 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |